Menactra
Trials 35 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 21 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02942277 Comparator | Oct 2016 → Jul 2020 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02810340 Comparator | Aug 2016 → Oct 2017 | meningococcal infection | PATH | Completed | No outcome recorded |
| Phase 1 | NCT02334462 Comparator | Jan 2015 → Mar 2016 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT03917654 Comparator | Apr 2019 → Jul 2021 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT03295318 Comparator | Nov 2017 → Aug 2018 | meningococcal meningitis | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01165242 Comparator | Aug 2010 → Feb 2011 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00700713 Comparator | Jun 2008 → Feb 2009 | meningitis, meningococcemia | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00700635 Comparator | Jun 2008 → May 2009 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00454909 Comparator | Apr → Oct 2007 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00269477 Comparator | Dec 2005 → Feb 2007 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04358731 Comparator | Dec 2019 → Mar 2021 | meningococcal infection | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT05794230 Comparator | Mar 2023 → Nov 2025 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04368429 Comparator | May → Nov 2020 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03964012 Comparator | Aug 2019 → Feb 2020 | meningococcal meningitis | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02752906 Comparator | Apr → Dec 2016 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00616421 Comparator | Mar 2008 → Apr 2009 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00450437 Comparator | Mar → Aug 2007 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT04450498 Comparator | Dec 2020 → Jul 2021 | meningococcal meningitis | Walvax Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT04224311 Comparator | Mar 2020 → Oct 2023 | meningococcal meningitis | Brigham and Women's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02633787 Background | Dec 2015 → Feb 2016 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01430689 Comparator | Sep 2011 → Jan 2014 | influenza | University of Maryland, Baltimore | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 57 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Menactra | “Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly...” NCT00777257 ↗46“This study compares the safety and immunogenicity of the Novartis Vaccines investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, with the licensed...” PMID 19476428 ↗ Jul 2009 “A meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4; Menactra; Sanofi Pasteur Inc, Swiftwater, Pa) was developed to improve...” PMID 16203934 ↗ Oct 2005 “Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.” PMID 21339701 ↗ Nov 2010 “Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Healthy Subjects Aged 9 Months to 55 Years in Vietnam” NCT02640404 ↗ “Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine)” NCT00700713 ↗ “Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine)” NCT01659996 ↗ “Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine.” NCT05298644 ↗ “Group 2 (n = 40) will receive Menactra® at a dose of 0.5 mL intramuscularly into the deltoid site.” NCT06834100 ↗ “Participants will receive Menactra® vaccine at age 9 months and 12 months, respectively.” NCT00384397 ↗ “2 doses of MenACYW conjugate vaccine compared to 2 doses of Menactra® vaccine” NCT05794230 ↗ “Participants received a single IM dose of Menactra® vaccine on Day 0.” NCT04368429 ↗ “following Menactra booster vaccination in study MTA77” NCT02633787 ↗ “a licensed MCV4 (Menactra®; MCV4-DT [n = 407]).” PMID 32209015 ↗ Mar 2020 “Menactra® vaccine and DAPTACEL® vaccine” NCT00355121 ↗ “booster dose of Menactra® vaccine” NCT00258856 ↗ “Hib #2, Prevnar 13#2, Menactra” NCT00505063 ↗ |
| Known as | Licensed meningococcal ACWY vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00616421 ↗ |
| Known as | MCV4 | “A phase IV randomized, observer-blind, controlled study compared the safety and immunogenicity of a quadrivalent meningococcal polysaccharide vaccine (MPV-4, MPV ACYW135) and...” PMID 37401618 ↗ Jul 20233“A meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4; Menactra; Sanofi Pasteur Inc, Swiftwater, Pa) was developed to improve...” PMID 16203934 ↗ Oct 2005 “The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one dose of Menveo® (MenACWY-CRM; Novartis) or...” PMID 21339701 ↗ Nov 2010 “A new tetravalent (A, C, Y, W-135) meningococcal conjugate vaccine (\[MCV4\], MenactraTM manufactured by Sanofi Pasteur Inc.) has been approved by Food and Drug Administration...” NCT00119080 ↗ |
| Known as | MCV4-DT | “a licensed MCV4 (Menactra®; MCV4-DT [n = 407]).” PMID 32209015 ↗ Mar 2020 |
| Known as | Menactra - Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine; Product No. 49281-589-05 | “Menactra - Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine; Product No. 49281-589-05” NCT01430689 ↗ |
| Known as | Menactra Vaccine | “Menactra® Vaccine” NCT00539032 ↗ |
| Known as | Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine | “Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly...” NCT00777257 ↗ |
| Known as | Meningococcal Diphtheria Toxoid Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01890759 ↗ |
| Known as | Meningococcal Polysaccharide Diphtheria Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00422292 ↗ |
| Known as | Meningococcal Polysaccharide Diphtheria Toxoid Conjugate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00269477 ↗ |
| Known as | Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01430689 ↗ |
| Known as | SP284 | “Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects” NCT02591290 ↗ |
| Known as | TetraMenD | “one or two doses of Menactra® (TetraMenD) administered in children less than 2 years of age” NCT00643916 ↗ |
| Modality | Vaccine | “Menactra® vaccine” NCT00258856 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT00269477 ↗ |